Partial
Partially Aligned
Patient Risk:
Medium
Summary
Several safety-related claims are supported by the provided label excerpts (tolerance, physical dependence/withdrawal, dizziness/drowsiness, dose-dependent respiratory depression). However, multiple claims are not supported because they are absent from the provided label sections (e.g., epilepsy/seizure indication, falls, comparisons vs other anti-seizure medications, and patent/generic availability). Full alignment cannot be confirmed because boxed warning/contraindications/complete dosing and other key label sections are not included in the provided text.
Category Scores
Accurate Statements
Long-term use of Ativan can lead to tolerance.
WARNINGS: DRUG ABUSE AND DEPENDENCE - Tolerance: “Tolerance to Ativan may develop from continued therapy.”
Long-term use of Ativan can lead to dependence.
WARNINGS: DRUG ABUSE AND DEPENDENCE - Physical Dependence/Dependence: “Ativan may produce physical dependence from continued therapy.”
Dependence can produce withdrawal symptoms when Ativan is discontinued.
WARNINGS: Physical Dependence: withdrawal signs/symptoms after abrupt discontinuation or significant dose reduction; acute withdrawal reactions including seizures; also Warning list item on life-threatening withdrawal.
Frequent or high-dosage use of Ativan can lead to physical dependence.
WARNINGS: dependence/withdrawal risk increases with longer treatment duration and higher daily dose; patients at increased risk include higher dosages and longer durations.
Physical dependence can make it challenging to discontinue Ativan without experiencing withdrawal symptoms.
WARNINGS: Physical Dependence: manifests by withdrawal signs/symptoms after abrupt discontinuation or significant dose reduction; recommends gradual taper to reduce withdrawal risk.
Ativan can cause dizziness, drowsiness, and balance problems.
ADVERSE REACTIONS: dizziness; sedation; unsteadiness/unsteadiness increases with age; includes drowsiness among benzodiazepine adverse reactions.
High doses of Ativan can cause respiratory depression.
ADVERSE REACTIONS: adverse reactions including respiratory depression are dose dependent with more severe effects at high doses; respiratory depression/apnea listed.
Respiratory depression from high doses of Ativan can be potentially life-threatening.
WARNING: “serious adverse outcomes, including respiratory depression, overdose, or death”; OVERDOSAGE: severe overdosage may develop respiratory depression and coma.
Unsupported Statements
Ativan (a benzodiazepine) is often prescribed for seizures associated with epilepsy.
No seizure/epilepsy indication is present in the provided INDICATIONS AND USAGE excerpt.
Long-term use of Ativan is linked to an increased risk of falls.
Provided label excerpts discuss sedation/unsteadiness increasing with age but do not mention falls.
Ativan has a higher risk of dependency and withdrawal compared with other anti-seizure medications.
No comparison to other anti-seizure medications appears in the provided excerpts; epilepsy/seizure context is not present.
Non-benzodiazepine options such as lamotrigine or topiramate may be more suitable for long-term use.
No alternative drug options (including lamotrigine/topiramate) are mentioned in the provided label excerpts.
Increasing the dosage of Ativan in epilepsy patients can exacerbate long-term risks including addiction and dependence.
No epilepsy-specific indication/dosing context is present in the provided excerpts; only general dependence/withdrawal risk language is shown.
Ativan's patents for epilepsy treatment have expired, making generic versions available.
No patent expiration or generic availability statements are included in the provided label excerpts.
Patent expiration does not necessarily address long-term risks associated with Ativan use.
No patent/generic discussion is included in the provided label excerpts, so the statement is not supported by label content.
Contradictions
Important Omissions
Boxed warning status and specific boxed-warning text (and contraindications) cannot be evaluated because boxed warning/contraindications sections were not included in the provided excerpts.
Importance:
High
Full dosage and administration guidance (including epilepsy-specific dosing, if any) is not included in the provided excerpts, limiting verification of dosing-related claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several safety-related claims that are supported by the label (dependence/withdrawal risk and dose-dependent respiratory depression) align with provided excerpts; however, unsupported claims (e.g., seizure/epilepsy use and fall risk) could mislead about indication and risk profile relative to label content. Complete boxed warning/contraindications are not assessable from the provided material.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided label excerpts, including seizure/epilepsy indication, fall risk, comparisons to other anti-seizure medications, and patent/generic statements. Key label sections (boxed warning, contraindications, and complete dosing) are missing.
Suggested Improvement
Restrict claims to what is explicitly present in the supplied label excerpts (e.g., dependence/withdrawal and dose-dependent respiratory depression). Remove unsupported patent/generic and epilepsy/seizure indication assertions, and avoid fall-risk statements unless the label text provided mentions falls.